Increasing unusual option volume: EOLS MXWL PAGP PBI PKI ARRY ASND NCR AMG MMC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat
February 5, 2019 8:02 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.05), $0.10 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $82.5 million versus the consensus estimate of $52.45 million.
Second Quarter of Fiscal 2019 Compared to First Quarter of Fiscal 2019
Net Product Sales for BRAFTOVI + MEKTOVI for the second quarter of fiscal 2019 was $22.7 million, compared to $14.0 million for the first quarter of fiscal 2019.Total Revenue for the second quarter of fiscal 2019 was $82.5 million, compared to $56.9 million for the prior quarter. The increase was primarily due to higher product sales and... More